{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:16:07Z","timestamp":1783350967296,"version":"3.54.6"},"reference-count":41,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,7,15]]},"DOI":"10.2169\/internalmedicine.0278-22","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:36:06Z","timestamp":1669790166000},"page":"2113-2121","source":"Crossref","is-referenced-by-count":4,"title":["Successful Steroid Treatment of Pembrolizumab-induced Agranulocytosis That Developed after Splenectomy in a Patient with Non-small-cell Lung Cancer"],"prefix":"10.2169","volume":"62","author":[{"given":"Shinichi","family":"Okuzumi","sequence":"first","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kamata","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsura","family":"Emoto","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Pathology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Otake","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Irie","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Chubachi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Ikemura","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Onoi K, Chihara Y, Uchino J, et al. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med 9: 1362, 2020.","DOI":"10.3390\/jcm9051362"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc) 51: 7-20, 2015.","DOI":"10.1358\/dot.2015.51.1.2250387"},{"key":"3","unstructured":"3. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393: 1819-1830, 2019."},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 135: 188-195, 2019.","DOI":"10.1016\/j.lungcan.2019.07.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. De Velasco G, Je Y, Boss\u00e9 D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5: 312-318, 2017.","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ye X, Hu F, Zhai Y, et al. Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019. Hematol Oncol 38: 565-575, 2020.","DOI":"10.1002\/hon.2743"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Delanoy N, Michot JM, Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6: e48-e57, 2019.","DOI":"10.1016\/S2352-3026(18)30175-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Omar NE, El-Fass KA, Abushouk AI, et al. Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review. Front Immunol 11: 1354, 2020.","DOI":"10.3389\/fimmu.2020.01354"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: iv119-iv142, 2017.","DOI":"10.1093\/annonc\/mdx225"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378: 1789-1801, 2018.","DOI":"10.1056\/NEJMoa1802357"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Couey MA, Bell RB, Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7: 165, 2019.","DOI":"10.1186\/s40425-019-0645-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79: 332-338, 2020.","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sinwar PD. Overwhelming post splenectomy infection syndrome - review study. Int J Surg 12: 1314-1316, 2014.","DOI":"10.1016\/j.ijsu.2014.11.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Juli\u00e1 A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 79: 366-371, 1991.","DOI":"10.1111\/j.1365-2141.1991.tb08042.x"},{"key":"15","first-page":"2031","volume":"8","author":"A Sprikkelman","year":"1994","unstructured":"15. Sprikkelman A, de Wolf JT, Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia 8: 2031-2036, 1994.","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146: 657-665, 2007.","DOI":"10.7326\/0003-4819-146-9-200705010-00009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kyaw MH, Holmes EM, Toolis F, et al. Evaluation of severe infection and survival after splenectomy. Am J Med 119: 276.e1-276.e7, 2006.","DOI":"10.1016\/j.amjmed.2005.07.044"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hisamatsu Y, Morinaga R, Watanabe E, Ohtani S, Shirao K. Febrile neutropenia in a patient with non-small cell lung cancer treated with the immune-checkpoint inhibitor nivolumab. Am J Case Rep 21: e920809, 2020.","DOI":"10.12659\/AJCR.920809"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer 99: 123-126, 2016.","DOI":"10.1016\/j.lungcan.2016.06.026"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Turgeman I, Wollner M, Hassoun G, Bonstein L, Bar-Sela G. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anticancer Drugs 28: 811-814, 2017.","DOI":"10.1097\/CAD.0000000000000520"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Barbacki A, Maliha PG, Hudson M, Small D. A case of severe pembrolizumab-induced neutropenia. Anticancer Drugs 29: 817-819, 2018.","DOI":"10.1097\/CAD.0000000000000661"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Naqash AR, Appah E, Yang LV, et al. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer 7: 169, 2019.","DOI":"10.1186\/s40425-019-0648-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Seguchi K, Nakashima K, Terao T, Takeshita G, Nagai T, Tanaka Y. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: a case report. Respir Med Case Rep 33: 101439, 2021.","DOI":"10.1016\/j.rmcr.2021.101439"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Tokumo K, Masuda T, Miyama T, et al. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Lung Cancer 119: 21-24, 2018.","DOI":"10.1016\/j.lungcan.2018.02.018"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kanai O, Nakatani K, Fujita K, Okamura M, Mio T. No need to hesitate: immune-related neutropenia and thrombocytopenia that improved by corticosteroids. Respirol Case Rep 9: e00799, 2021.","DOI":"10.1002\/rcr2.799"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Liu C, Ding L, Zhu YH, Chen C. A rare case of lung carcinoma acquires multidrug-resistant <i>Klebsiella pneumoniae<\/i> pneumonia radiologically mimicking metastasis caused by nivolumab therapy-associated neutropenia. Ther Clin Risk Manag 13: 1375-1377, 2017.","DOI":"10.2147\/TCRM.S144681"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tozuka T, Sugano T, Noro R, et al. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxf Med Case Rep 2018: omy094, 2018.","DOI":"10.1093\/omcr\/omy094"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32: 322-324, 2009.","DOI":"10.1097\/CJI.0b013e31819aa40b"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Meti N, Petrogiannis-Haliotis T, Esfahani K. Refractory neutropenia secondary to dual immune checkpoint inhibitors that required second-line immunosuppression. J Oncol Pract 14: 514-516, 2018.","DOI":"10.1200\/JOP.18.00177"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Simeone E, Grimaldi AM, Esposito A, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 8: 240, 2014.","DOI":"10.1186\/1752-1947-8-240"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Wo\u017aniak S, Mackiewicz-Wysocka M, Krokowicz \u0141, Kwinta \u0141, Mackiewicz J. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report. Oncol Res Treat 38: 105-108, 2015.","DOI":"10.1159\/000377650"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Patel R, Pai L. Immunotherapy-induced severe neutropenia with neurotoxicity: a case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma. J Oncol Pharm Pract 26: 730-734, 2020.","DOI":"10.1177\/1078155219862341"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Takahashi A, Kubo A, Mizuno S, et al. Bicytopenia in primary lung melanoma treated with nivolumab. Intern Med 58: 827-831, 2019.","DOI":"10.2169\/internalmedicine.1011-18"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D. Ipilimumab-induced neutropenia in melanoma. J Investig Med High Impact Case Rep 4: 2324709616661835, 2016.","DOI":"10.1177\/2324709616661835"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Meyers DE, Hill WF, Suo A, Jimenez-Zepeda V, Cheng T, Nixon NA. Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. Exp Hematol Oncol 7: 6, 2018.","DOI":"10.1186\/s40164-018-0098-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. du Rusquec P, Saint-Jean M, Brocard A, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 37: 348-350, 2014.","DOI":"10.1097\/CJI.0000000000000041"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Wei G, Nwakuche U, Cadavid G, Ajaz A, Seiter K, Liu D. Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Exp Hematol Oncol 1: 3, 2012.","DOI":"10.1186\/2162-3619-1-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Bryant AR, Perales MA, Tamari R, Peled JU, Giralt S. Severe pembrolizumab-associated neutropenia after CD34<sup>+<\/sup> selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bone Marrow Transplant 53: 1065-1068, 2018.","DOI":"10.1038\/s41409-018-0142-4"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Wang AY, Kline J, Stock W, et al. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 26: 1025-1027, 2020.","DOI":"10.1016\/j.bbmt.2020.01.021"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Wright Z, Brown A. High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. Blood Adv 1: 1306-1308, 2017.","DOI":"10.1182\/bloodadvances.2017008607"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Laurain PA, Landrin T, Souidi S, Beuzeboc P, Scott\u00e9 F. Atypical extended immune-related neutropenia in patient treated with pembrolizumab. Eur J Cancer 130: 269-271, 2020.","DOI":"10.1016\/j.ejca.2020.02.005"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/14\/62_0278-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T03:22:07Z","timestamp":1689391327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/14\/62_0278-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,15]]},"references-count":41,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0278-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,15]]},"article-number":"0278-22"}}